In patients with ventilator-associated pneumonia (VAP), guidelines recommend antibiotic therapy adjustment according to microbiology results after 72 h. Circulating procalcitonin levels may provide evidence that facilitates the reduction of antibiotic therapy.
In a multicentre, randomised, controlled trial, 101 patients with VAP were assigned to an antibiotic discontinuation strategy according to guidelines (control group) or to serum procalcitonin concentrations (procalcitonin group) with an antibiotic regimen selected by the treating physician. The primary end-point was antibiotic-free days alive assessed 28 days after VAP onset and analysed on an intent-to-treat basis.
Procalcitonin determination significantly increased the number of antibiotic free-days alive 28 days after VAP onset (13 (2–21) days versus 9.5 (1.5–17) days). This translated into a reduction in the overall duration of antibiotic therapy of 27% in the procalcitonin group (p = 0.038). After adjustment for age, microbiology and centre effect, the rate of antibiotic discontinuation on day 28 remained higher in the procalcitonin group compared with patients treated according to guidelines (hazard rate 1.6, 95% CI 1.02–2.71). The number of mechanical ventilation-free days alive, intensive care unit-free days alive, length of hospital stay and mortality rate on day 28 for the two groups were similar.
Serum procalcitonin reduces antibiotic therapy exposure in patients with ventilator associated pneumonia.
Ventilator associated pneumonia (VAP) is the leading cause of death from nosocomial infection in the USA 1–3. The mortality attributable to VAP has been reported to range between 24% and 50% 4, 5. The estimated excess cost for an episode of VAP can be as high as $40,000 per patient 5, 6. Based on an estimate of 250,000 cases of VAP annually, the cost of treatment easily approaches $10 billion in the USA alone 7.
At the present time, there is no gold standard for the diagnosis of VAP and the optimal approach for diagnosing VAP remains to be defined 8–10. Prompt initiation of broad-spectrum antibiotic therapy is a cornerstone of treatment of VAP because even relatively short delays in administering adequate antibiotic therapy are associated with an increased mortality rate 11–13. Unfortunately, exposure to antibiotics, especially for ≥7 days, has been associated with subsequent emergence of infection with antibiotic-resistant bacteria and worse outcome 14–18. Clinicians managing patients with suspected VAP should employ antimicrobial treatment strategies that minimise prolonged and potentially unnecessary antibiotic exposure to curtail resistance 19. In this context, the concept of de-escalation therapy is emerging as an effective strategy to reduce the development of bacterial resistance in patients treated for VAP 10, 20. Appropriately shortening the treatment duration is an important aspect of decreasing antibiotic-associated costs, minimising selection pressures for resistant organism in the ICUs and improving outcomes 8. The most recent treatment guidelines by the American Thoracic Society (ATS) and Infectious Disease Society of America (IDSA) have put forth a strategy to address early stoppage of antibiotics 21. Accordingly, upon suspicion of VAP, lower respiratory tract sampling for cultures are obtained and empiric broad-spectrum antibiotics started. A systematic re-evaluation at 48 to 72 h, should allow for strongly considering stopping antibiotics if the patient is improving and cultures are negative. Should the culture results be positive and the patient has improved, then antibiotics being administered are tailored to the culture results, including potential for monotherapy 10. Regrettably, this treatment algorithm often is not adhered to in daily clinical practice 19. Some authors have suggested that inability to obtain uncontaminated lower respiratory tract secretions and the pressures to treat an increasingly ill population are some of the factors that limit adherence to this approach 22.
Procalcitonin, the precursor molecule of calcitonin, is up-regulated in severe bacterial infections and sepsis 23, 24. Procalcitonin may be considered as a valuable biomarker for the diagnosis of bacterial infections, including VAP, where its levels are correlated with outcome 25, 26. Its usefulness for guiding antibiotic therapy has been shown in patients admitted for community-acquired respiratory tract infections 27–29. It has been recently suggested that serial measurements of procalcitonin allow a reduction in the duration of antibiotic therapy without resulting in more adverse outcomes in critically ill patients with severe sepsis and septic shock 30. Despite the growing body of literature in favour of this biomarker 27–31, it is unknown whether procalcitonin enables a refinement in the current ATS/IDSA antibiotic stoppage strategy in VAP. Therefore, we undertook this multicentre, randomised trial to determine if procalcitonin serum evaluation reduces antibiotic exposure in patients with clinically diagnosed VAP with a similar clinical and laboratory outcome.
Setting and study population
This is a multinational, randomised, controlled open intervention trial in patients with VAP requiring treatment at an intensive care unit (ICU) performed in seven ICUs (UMass Memorial Medical Center, Worcester, MA, USA; University Hospital Lausanne, Switzerland and University Hospital, Basel, Switzerland). The results are reported following the consolidated standards of reporting trials statement (fig. 1⇓) 32. We compared antibiotic therapy duration in patients treated according to current guidelines (control group) with patients in who antibiotic treatment was guided by serum procalcitonin levels (procalcitonin group). The study was approved by the institutional review boards of all participating institutions and registered in the Current Controlled Trials Database as “ProVAP”-Study (ISRCTN61015974) 33. Written informed consent was obtained from all included patients or their legal representatives. All data were held and analysed by the authors.
ICU patients intubated for mechanical ventilation for ≥48 h were eligible for the study if they met all the following criteria: 1) >18 yrs; 2) clinically diagnosed VAP as defined by the ATS guidelines (new or persistent infiltrate on chest radiography associated with at least two of the following: purulent tracheal secretions, temperature >38°C or, leukocyte count >11,000 μL or <3,000 μL) 21. Patients were excluded it they 1) were pregnant; 2) were enrolled in another trial; 3) had received immunosuppressants or long-term corticosteroid therapy (≥0.5 mg·kg−1·day−1 for >1 month); 4) were severely immunosuppressed, including acquired immunodeficiency syndrome; and 5) had a coexisting extrapulmonary infection diagnosed between day 1 and 3 requiring antibiotic therapy for >3 days.
Patients were randomly assigned to one of the two approaches after agreement of the attending physician. Randomisation was through arbitrary allocation to one of the two treatment assignments based on sealed, opaque envelopes. Block size was 20 envelopes. Treating physicians were not aware of envelope contents before randomisation. In both groups, antibiotic therapy was started at inclusion (day 0), according to the decision of the attending physician, who was unaware of procalcitonin levels. Educational sessions, posters and instruction cards highlighting the current standard antibiotic de-escalation strategy according to the ATS were provided to attending physicians and those responsible for patient's treatment decisions 21. Thereby, particular emphasis was set on the recommendations regarding the stoppage of antibiotics according to microbiology results after 72 h and duration of antibiotic therapy as suggested by the ATS 21.
After 72 h (day 2), daily procalcitonin levels were notified to the attending physician, automatically and/or by personal communication, for patients randomised to the procalcitonin group. Thereafter, the physician in charge was advised to classify the patients into four groups, according to the probability of ongoing bacterial infection 27. A procalcitonin level of <0.25 μg·L−1 suggested the absence of VAP and discontinuation of antibiotics was strongly encouraged. A procalcitonin level between 0.25 and 0.5 μg·L−1 or a decrease by ≥80% compared with day 0 indicated that bacterial infection was unlikely and reduction or discontinuation of antibiotics was encouraged. A procalcitonin level ≥0.5 μg·L−1 or decrease by <80% compared with day 0 was considered to indicate unresolved bacterial infection and reduction or discontinuation of antibiotics was discouraged. A procalcitonin level of >1 μg·L−1 strongly suggested unresolved bacterial infection and antibiotic discontinuation was strongly discouraged. After day 2, evaluation of procalcitonin levels was performed by comparing daily procalcitonin levels with the immediately previous value. Re-evaluation of the clinical status and measurement of serum procalcitonin levels were performed daily for both groups up to day 10 after inclusion. Attending physicians responsible for patients in the control group remained unaware of procalcitonin throughout the study.
Measurement of serum procalcitonin
Measurements were done using a time-resolved amplified cryptate emission technology assay (Kryptor® PCT, Brahms AG, Hennigsdorf, Germany) 27 with a functional assay sensitivity of 0.06 μg·L−1, approximately four-fold above mean normal levels 34. Assay time is <20 min and results were routinely available within 1 h.
Drug selection was left to the discretion of the treating physicians, including any adaptation considered necessary as a function of clinical, laboratorial, radiological or microbiological results, including bacteriology susceptibility patterns. Upon inclusion in the study and before initiation of antibiotic therapy, sampling of respiratory secretions (endotracheal aspirates, bronchoalveolar lavage, or protected brush specimens) was strongly recommended. The attending and resident physicians in participating ICUs were periodically re-educated on standard antibiotic reduction strategy recommendations 21. In all situations, treating physicians retained control of antibiotic treatment and were empowered to refrain from antibiotic discontinuation if the duration of antibiotic treatment was considered inadequate or a patient's condition deteriorated.
Baseline assessment and follow-up
At the time of enrollment the following information was recorded from each subject: age, sex, pre-existing comorbidities, severity of the underlying medical condition(s), primary reason for initiating mechanical ventilation, duration of prior mechanical ventilation, use of any antibiotics within 14 days of VAP onset, presence of infiltrates on chest radiography, fever ≥38°C, leukocytosis or leukopenia, purulent tracheal secretions, body temperature, heart rate, mean arterial pressure, oxygen saturation, ratio of arterial oxygen tension (Pa,O2) to inspiratory oxygen fraction (FI,O2), leukocyte counts and serum procalcitonin values (table 1⇓).
The following indices were calculated: clinical pulmonary infection score (CPIS) score, simplified acute physiologic score (SAPS) II; organ dysfunction and/or infection score (ODIN) and; sepsis-related organ failure assessment score (SOFA).
During the 28 day follow-up period the following information was recorded: body temperature; heart rate; mean arterial pressure; Pa,O2; Pa,O2/Fi,O2; CPIS; SOFA; leukocyte counts and serum procalcitonin values for 10 consecutive days; mechanical ventilation status and antibiotic use daily throughout the 28-day study period; vital signs; leukocyte counts and SOFA scores at days 14, 21 and 28; and the patient's status at discharge from the hospital. Any antibiotic use was recorded daily up to day 28. The number of antibiotic-agent days, i.e. number of antimicrobial agents per day × number of days) was also documented. We calculated the number of antibiotic-free days alive as the number of days during the 28 days after living patients had been randomised and had not received any antibiotics, as previously described 16. VAP-related clinical and/or radiological deterioration was defined as an increase in CPIS of more than two points.
The primary end-point was the number of antibiotic-free days alive assessed 28 days after enrollment in the study. Any antibiotic exposure after inclusion, i.e. total antibiotic exposure days and total antibiotic-agent days, regardless of indication, was taken into account for antibiotic exposure analyses. Antibiotic therapy discontinuation related to death was considered a censored event.
Secondary end-points were the number of mechanical ventilation-free days, the number of ICU-free days alive, the evolution of the signs and symptoms potentially linked to pulmonary infection, Sa,O2, Pa,O2/Fi,O2, the evolution of the SOFA, ODIN and CPIS scores, length of hospital stay, the VAP-related clinical deterioration rate and overall mortality at 28 days. Patients discharged prior to the end of the study (28 days) were followed-up at home or in the post-acute institution for the outcomes of interest.
The trial was designed to demonstrate the superiority of the algorithm incorporating procalcitonin in terms of increasing the number of antibiotic-free days in patients alive within 28 days of inclusion in the study. The sample size was calculated based on the antibiotic-use days in a prior study 16. Considering 13 antibiotic-free days in the control group and 18 antibiotic-free days in the procalcitonin group, a sample size of 84 patients (42 per group) was necessary to detect a significant difference in antibiotic-free days alive between both groups with a power of 90% and an α error of 0.05 using a two-tailed test. Assuming 8% lost to follow-up, we planned the inclusion of 100 subjects.
Discrete variables are expressed as counts (%) and continuous variables as mean±sd or median (interquartile range (IQR)). End-points were predefined and analysed on the basis of intention-to-treat. Comparability of the control group and the procalcitonin group was analysed by Chi-squared test or Fisher's exact test for categorical variables and nonparametric Mann–Whitney U-test or unpaired t-test for continuous variables, as appropriate. Cumulative-events curves were estimated with the Kaplan–Meier method. Time to discontinuation of antibiotic treatment was compared between the two study groups by use of the log-rank test. Cox proportional hazards regression analysis was used to evaluate the occurrence of events on day 28, adjusting by age, microbiology of respiratory samples and centre effect (“a priori decision”).
Baseline characteristics of the patients
During the study period, of the 164 patients with VAP screened for eligibility, 101 were eligible and randomised into the procalcitonin group (n = 51) or into the control group (n = 50) (fig. 1⇑). The clinical characteristics of these 101 patients at baseline were similar, except that the ODIN score was slightly higher (p = 0.042) for the control group (table 1⇑). Three fourths of the patients had received antibiotics within 14 days prior to inclusion in the study, without a significant difference between the groups (p = 0.119). At inclusion, serum procalcitonin levels were <0.25 μg·L−1 in 29 patients (15 in the control group and 14 in the procalcitonin group; p = 0.82), 0.25 to 0.499 μg·L−1 in 13 patients (four in the control group and nine in the procalcitonin group; p = 0.23) and ≥0.5 μg·L−1 in 56 patients (30 in the control group and 26 in the procalcitonin group; p = 0.42). Median (IQR) procalcitonin levels in patients pre-treated with antibiotics were 0.73 (0.22–2.36) μg·L−1, which was not significantly different from patients without antibiotic exposure 0.72 (0.15–2.36) μg·L−1.
Microbiological investigation of respiratory tract secretion samples was performed in 97 (96%) patients. In 74 (73%) patients a causative microorganism was identified. The rate of positive bacterial cultures was similar in the control group and the procalcitonin group (76% versus 71%). Microorganisms considered responsible for VAP are listed in table 2⇓. In both groups the most frequently isolated Gram-negative microorganism was Pseudomonas aeruginosa followed by Klebsiella spp. Most commonly isolated Gram-positive bacteria were methicillin-sensitive Staphylococcus aureus and methicillin-resistant S. aureus. Microbiological cultures from others sites were positive in 20 patients (10 control group versus nine procalcitonin group; p = 0.625). In the control group, infection sites were catheter tips (two Staphylococcus non-aureus and one coagulase negative Staphylococcus), spinal fluid (one Streptococcus viridans, one S. aureus), urine (one Enterococcus), wound swabs (one coagulase negative Staphylococcus, one methicilin-resistant S. aureus, one Enterococcus) and blood cultures (one S. aureus). Correspondingly, in the procalcitonin group, infections sites were catheter tips (one Candida albicans), spinal fluid (two Streptococcus pneumonia), urine (one Enterococcus), wound swabs (one Enterococcus, vancomycin-resistant Enterococcus, one Enterobacter cloacae and Proteus mirabilis), faeces (one Clostridium difficile), and blood cultures (one Candida albicans).
Primary end-point: reduction of antibiotic exposure
The median (IQR) number of antibiotic-free days alive within 28 days of diagnosis of VAP was significantly higher in the procalcitonin group than in the control group (13 (2–21) versus 9.5 (1.5–17) days; fig. 2a⇓). This translated into a reduction in the overall duration of antibiotic therapy of 27% in the procalcitonin group (15 (10–23) versus 10 (6–16) days; p = 0.038). The total number of antibiotic-agent days was higher in the control group than in the procalcitonin group (1,341 versus 1,077 days). At the end of serial procalcitonin measurements (day 10), the rate of antibiotic discontinuation was significantly higher in the procalcitonin group compared with patients treated according to guidelines (hazard rate 2.235; 95% CI 1.077–4.64; p = 0.031). Cox regression-based adjustment of the baseline variables did not substantially modify these findings. The adjusted rate for antibiotic discontinuation of patients in the procalcitonin group versus those in the control group on day 28 was 1.66 (95% CI, 1.02–2.71; fig. 2b⇓) after adjustment for age, respiratory tract culture results and centre effect.
Overall, the median (IQR) duration of antibiotic therapy for VAP was 11 days 6–17. Antibiotic therapy was continued beyond 7 days in 82% of subjects in the control group and in 65% in the procalcitonin group, (p = 0.044; fig. 3a⇓). In the 28 days following the diagnosis of VAP, antimicrobial monotherapy was administered in 22% of cases (eight control and 14 procalcitonin group); combination therapy with two antimicrobials in 24% (13 control and 11 procalcitonin group); three antimicrobials in 21% (12 control and nine procalcitonin group); four antimicrobials in 17% (eight control and nine procalcitonin group); and five or more antimicrobials in 16% (nine control and seven procalcitonin group). The most commonly administered antibiotics in both groups included piperacillin/tazobactam in 78 (77%) patients, vancomycin in 44 (44%), meropenem/imipenem in 31 (31%), levofloxacin in 29 (29%), and amoxicillin/clavulanic acid in 25 (25%). Appropriate initial empiric antibiotic therapy, defined as a regimen combining an aminoglycoside or a fluoroquinolone plus a betalactam or an antipseudomonal carbepenem, was given in 86% of the cases without differences between the groups (p = 0.345). After 72 h, combination therapy with two or more drugs could be reduced to monotherapy in 54% of patients in the procalcitonin group compared with 28.6% of patients in the control group (p = 0.008; fig. 3b⇓).
A microbiologically confirmed VAP influenced maintenance of antibiotic therapy in the control group (hazard rate 2.30, 95% CI 1.11–4.77) but not in the procalcitonin group (hazard rate 1.17, 95% CI 0.59–2.32). Correspondingly, patients with microbiologically diagnosed VAP (n = 73) had significantly more median (IQR) antibiotic-free days alive in the procalcitonin group compared with the patients treated in the control group (14 (1–21) versus 7 (0–13.5) days; p = 0.017). Conversely, the number of antibiotic-free days alive were similar in those with negative microbiology (p = 0.563). Neither in the procalcitonin group nor in the control group did CPIS scores influence discontinuation of antibiotic therapy (p = 0.845 and p = 0.175).
Reasons for antibiotic discontinuation in the control group were clinical and laboratorial improvement (28%, n = 14), extubation (16%, n = 8), negative microbiology results (16%, n = 8) and improvement in CPIS score (14%, n = 7). In 10% (n = 5) of the cases antibiotic therapy was maintain beyond 28 days. A total of eight patients deceased while on antibiotic therapy for VAP. Strategies for discontinuation of antibiotic therapy in VAP included cessation of monotherapy (20%, n = 10), dual therapy (14%, n = 7), or triple therapy (2%, n = 1), de-escalation from triple to dual therapy (16%, n = 8), de-escalation from triple or dual to monotherapy (22%, n = 11) or adjustment of antibiotics without reduction of the number of antibiotic agents (26%, n = 13). Median time to cessation of monotherapy was 9 days (5–12) and to de-escalation from dual to monotherapy was 2 days (1–5). In the procalcitonin group, a total of eight patients with improved CPIS scores received prolonged antibiotic treatment despite low procalcitonin values. In four (8%) cases, positive blood cultures with Gram negative bacilli were observed and in another four (8%) cases, treating physicians decided to prolong antibiotic treatment due to documented pulmonary infection with Gram negative bacilli (Acinetobacter baumanii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Klebsiella). Duration of antibiotic therapy for VAP was significantly longer in these patients (15 (14–19) versus 7 (4–16) days; p = 0.023). The incidence of acquired or persistent microorganisms up to 28 days after VAP onset did not differ between randomised groups (16 versus 13 days; p = 0.5149; table 3⇓).
Secondary end-points: clinical and laboratory outcome
None of the secondary outcome events (table 4⇓) or physiologic changes seen from day 1 through day 28 differed significantly between patients in the control and procalcitonin groups (fig. 4⇓). The two groups had a similar median (IQR) number of mechanical ventilation and ICU-free days alive. In both groups, median mechanical ventilation- and ICU-free days alive were lower for patients with infection due to Gram-negative bacilli and MRSA. VAP-related clinical and radiological deterioration rate did not differ in both groups. Hospital discharge rate and post-discharge institution placement pattern was also comparable in both groups.
Deaths in the two groups were due to traumatic brain injury/subarachnoid haemorrhage (four in the control and four in the procalcitonin group), septic shock (two in the control and one in the procalcitonin group), respiratory failure (three in the control and one in the procalcitonin group), cardiogenic shock (one in the control and one in the procalcitonin group), acute respiratory distress syndrome (one in the control group), multiorgan failure (one in the procalcitonin group) and acute liver failure (one in the control group). Patients who died during their hospitalisation had significantly higher levels of procalcitonin on admission than those who did not die (median (IQR) 1.29 (0.21–2.00) versus 0.58 (0.45–5.43), p = 0.02), higher SAPS II scores (47.5 (43.4–55) versus 38 (31–47); p<0.001), and higher SOFA scores (9 (7–13.8) versus 6 (6–9); p = 0.004). CPIS scores (p = 0.935) and leukocyte counts (p = 0.309) were similar in subjects who died and those who did not die.
Procalcitonin levels at VAP diagnosis correlated significantly with the increasing severity of the disease, as defined by the SAPS II score (r2 = 0.358, p<0.001), the number and the severity of acute organ failures related to ICU mortality (r2 = 0.474, p<0.001), and the presence or absence of organ dysfunctions and/or infection (r2 = 0.254, p = 0.015). Circulating procalcitonin levels decreased similarly within 28 days of VAP onset in both randomised groups (fig. 4⇑).
In this multicentre, randomised clinical trial we observed a benefit of incorporating procalcitonin into the antibiotic reduction strategy suggested by current ATS/IDSA guidelines. The average number of antibiotic-free days alive from day 1 to day 28 was 27% higher for patients who had been randomised to the procalcitionin group than for patients assigned to the control group. The procalcitonin-guided approach allowed to reduce the overall number of antibiotic-free days alive at 28 days by the same amount as reported by Chastre et al. 16 in his landmark trial, which randomised patients to receive 8 or 15 days of antibiotic therapy for VAP. Procalcitonin-guided strategy was able to significantly reduce the median duration of overall antibiotic treatment by one third, i.e. from 15 to 10 days. Despite precise guidelines based on strong evidence for reducing the duration of antibiotic treatment for VAP to 8 days 16, such practice has not been reported to be successfully translated in current clinical practice 21. Accordingly, the long duration of antibiotic treatment in the control group in our study may be close to the current clinical practice in many centres. This seems to be true particularly for USA critical care centres, in which we observed a significantly longer median (IQR) overall duration of antibiotic therapy (15 (9–23) versus 11 (6–17) days; p = 0.02) and antibiotic therapy for VAP (14.5 (7–20) versus 10 (5–15) days; p = 0.027) as well as higher total number of antibiotic-agent days (26.6 (18.5–53.5) versus 12 (7–24) days; p<0.001, respectively) compared with European centres. In contrast, the median overall antibiotic duration of 10 days in the procalcitonin-guided group, very close to the 8 days targeted by the recommendations for VAP, suggest that the use of this biomarker in addition to the other usual clinical, laboratory and radiological information may lead to effective bedside antibiotic discontinuation.
The benefit associated with procalcitonin-guidance was achieved by an increase in the number of antibiotic-free days alive after VAP onset. The primary end-point of this study, to evaluate whether a procalcitonin-guided strategy provides a real benefit in decreased overall antibiotic exposure, was accomplished by assessing the number of days without any antibiotic exposure. In this context, it represents a rather robust, i.e. conservative outcome.
The absence of differences in outcome parameters including the evolution of clinical and radiological signs and symptoms of pulmonary infection, the number of mechanical ventilation-free days alive, the number of ICU-free days alive, the length of hospital stay and overall mortality suggest that procalcitonin-guided antibiotic reduction is not associated with a worse outcome in VAP. This also supports the concept that complications associated with long-term broad-spectrum antibiotic use may also have been avoided 7.
Currently, duration of antibiotic therapy in VAP is based on empirical rules and physician's preference 10, 16. De-escalation of therapy is advocated for as an appropriate strategy for managing antibiotics for VAP. The de-escalation approach provides clinical balance between one extreme of using broad-spectrum, empiric antimicrobial agents as the sole treatment strategy and the other extreme of delaying the initiation of targeted therapy pending bacteriologic results 35. The most recent ATS/IDSA guidelines emphasise the need for early and appropriate antibiotic therapy followed by de-escalation whenever possible, based on culture and patient response 21. Clinical strategies, based on evidence of clinical improvement, as defined by reduction in serial CPIS or improvement of the Pa,O2/Fi,O2 ratio at days 3 to 5, have also succeeded in limiting antibiotic use in patients with mild VAP in the context of clinical trials 15, 17, 18, 36. Furthermore, cultures obtained from respiratory tract sampling consistently result in a change of antibiotic regimen allowing narrowing of antibiotics or monotherapy once microorganisms and theirs susceptibilities have been identified 37, 38. Such practices were included in our strategies to reduce antibiotic exposure in both groups and may have contributed to our results.
It has been proposed that biomarkers might contribute to customise the duration of antibiotic treatment at a patient level, resulting in a greater tendency to limit or discontinue antibiotics 19, 30. Procalcitonin concentration closely parallels the severity and evolution of infection, including VAP, for which it has also a prognostic value 39–41. This was also observed in our patients. We believe it is fair to assume that physicians taking care of patients with known (low) procalcitonin levels (procalcitonin group) tended to feel more confident in discontinuing antibiotic therapy than physicians taking care of patients, in whom procalcitonin levels were unknown (control group). Procalcitonin levels might have facilitated the discontinuation of one or all antimicrobial agents at the same time. This might explain why not only the number of antibiotic-free days alive was higher in patients randomised to the procalcitonin group, but also why patients randomised to the procalcitonin group received a smaller amount of antibiotic-agent days. In agreement with others, we observed a wide variation in serum procalcitonin concentrations at onset of VAP (fig. 5⇓) 41, 42. This suggests that individual VAP patients may require different lengths of antibiotic therapy according to different virulence of the causative microorganism and to individual host response to infection, factors potentially reflected by the evolution of serum procalcitonin levels 30.
The utility provided by the procalcitonin-guided strategy was more impressive in those patients with microbiologically diagnosed VAP. In our study, despite a high proportion of previous antibiotic exposure, VAP was microbiologically documented in 74% of the patients. This may again support that a procalcitonin-guided antibiotic discontinuation might provide an additional benefit to the currently applied microbiologically-guided de-escalation strategy.
In contrast to the impressive reduction in antibiotic exposure reported in patients admitted with community-acquired respiratory tract infections 27–29, we achieved only modest gains in antibiotic use for VAP. This may be due to additional difficulties in the interpretation of procalcitonin results in such ill patients, potentially related to higher proportion of previous systemic inflammatory response syndromes, multiorgan failure, previous infection and/or surgery, all known to raise the procalcitonin levels 25,43.
Importantly, in the present study, procalcitonin kinetics assessed up to day 10 was used to support antibiotic discontinuation following ≥72 h empiric antimicrobial therapy for VAP. Hence, the results of this study do not allow primarily withholding of antibiotics based on procalcitonin levels at the time of VAP onset.
Our study has several limitations. First, we included a relatively small number of patients and our results should not be generalised to other settings such as hospital-acquired pneumonia and noncritically ill patients. It may not apply in the context of de-escalation strategies other then those suggested by ATS/IDSA guidelines. Secondly, these findings have to be validated in a larger cohort of patients, allowing sub-group analyses for selected populations, in whom infections may be more difficult to treat, e.g. severe chronic obstructive pulmonary disease and immunocompromised patients. Thirdly, our intervention was performed in a clinical setting, in which the final decision to de-escalate antibiotic treatment was left to the discretion of the attending physician. Thereby and in contrast to the study by Chastre et al. 16, physicians were not obliged to always conform to the study protocol. However, protocol overruling would result in a conservative bias, potentially underestimating the benefit of a procalcitonin-guided approach. Given the complexity of monitoring adherence to guidelines, we believe that it is fair to expect results of a study mimicking daily bedside practice to be more likely reproduced in a noninvestigation setting. Fourthly, we should emphasise that our trial was not designed to test the potential efficacy of a shorter duration of antibiotic treatment. In contrast, we demonstrated that a shorter duration of antibiotic therapy was not associated with a worse outcome. Finally, we did not conduct a formal cost-benefit study. Larger clinical trials are needed to explore the overall clinical and economic impact of the reduction of exposure to antibiotics in VAP patients. Strengths from our study are the multicentric design, the primary end-point evaluating the total number of antibiotic-free days alive up to 28 days irrespective of the indication for antibiotic therapy and the potential reproducibility of the results in daily clinical practice.
In conclusion, serum procalcitonin reduces antibiotic exposure in critically ill patients treated for VAP.
The study is registered in the Current Controlled Trials Database as “ProVAP”-study (ISRCTN61015974) .
D. Stolz was supported by grants from the Swiss National Foundation (Bern, Switzerland), the Margarete und Walter Liechtenstein Foundation (Basel, Switzerland) and the “Freiwillige Akademische Gesellschaft Basel” (Basel, Switzerland). N. Thakkar was supported by the Will Rogers Foundation (Toluca Lake, CA, USA). Additional funding was granted by the Clinic of Pulmonary Medicine, University Hospital Basel. Funding obtained from Brahms AG (Hennigsdorf, Germany) was used for assay material and logistics. The sponsors of this investigator-initiated project had no involvement in design and conduct of the study, collection, management, analysis, and interpretation of the data, nor in the preparation, review, and approval of the manuscript or decision to submit the manuscript.
Statement of interest
A statement of interest for the study itself can be obtained from www.erj.ersjournals.com/misc/statements.dtl
The current authors would like to thank A. Meyer (Clinic of Pulmonary Medicine and Respiraotry Cell Research, University Hospital, Basel, Switzerland), S. Heard, J. Longtine and K. Longtine (Dept of Anesthesiology, UMass Memorial Medical Center, University of Massachusetts, Worcester, MA, USA) for continuous support throughout the study, and A. Schötzau (Schötzau and Simmen Statistics, Basel) for statistical advice.
- Received March 31, 2009.
- Accepted September 2, 2009.
- © ERS Journals Ltd